Skip to main content
    C

    CytomX Therapeutics Inc (CTMX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.99
    -0.06 (-2.70%)

    Market Cap: $444.73M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    CytomX Therapeutics Inc (CTMX) Financials: Revenue, Profit and Cash Flow

    Updated Nov 5, 2026. Financial statements from company filings, amounts in US dollars.

    CytomX Therapeutics reported revenue of $76.20M for the fiscal year ended Dec 31, 2025, down 44.8% from the year before. That year, net income was -$17.37M with a net margin of -22.8%, operating cash flow was -$75.59M and free cash flow was -$75.81M. The quarter ended Sep 30, 2026 had revenue of $1.69M and net income of -$20.00M.

    Revenue and Margins

    The operating margin was -29.3% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from $15.04M, a compound annual rate of 19.8%.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$76.20M-44.8%100.0%-29.3%-22.8%
    Dec 2024$138.10M+36.4%100.0%18.1%23.1%
    Dec 2023$101.21M+90.4%100.0%-6.4%-0.6%
    Dec 2022$53.16M+42.5%100.0%-190.6%-186.8%
    Dec 2021$37.31M-45.5%100.0%-311.0%-310.5%
    Dec 2020$68.43M+154.4%100.0%-117.7%-94.7%
    Dec 2019$26.90M-54.8%100.0%-525.9%-493.7%
    Dec 2018$59.50M-16.9%100.0%-130.9%-142.2%
    Dec 2017$71.62M+376.1%100.0%-64.6%-60.2%
    Dec 2016$15.04MN/A100.0%-396.1%-391.5%
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the company posted a net loss after a profit the year before. In the quarter ended Sep 2026, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Revenue$76.20M$138.10M$101.21M$53.16M$37.31M$68.43M$26.90M$59.50M$71.62M$15.04M
    Gross profit$76.20M$138.10M$101.21M$53.16M$37.31M$68.43M$26.90M$59.50M$71.62M$15.04M
    Research and development$68.73M$83.38M$77.68M$111.65M$114.19M$112.94M$131.62M$103.87M$92.28M$54.76M
    Operating income-$22.36M$25.00M-$6.48M-$101.33M-$116.04M-$80.54M-$141.48M-$77.87M-$46.26M-$59.59M
    Net income-$17.37M$31.87M-$569.00K-$99.32M-$115.87M-$64.82M-$132.82M-$84.60M-$43.10M-$58.90M
    EBITDAN/AN/AN/A-$98.60M-$113.15M-$78.23M-$141.24M-$77.76M-$44.25M-$56.26M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$1.69M$1.42M$10.26M$663.00K$5.96M$18.66M$50.92M$38.09M$33.43M$25.11M$41.46M$26.61M
    Gross profit$1.69M$1.42M$10.26M$663.00K$5.96M$18.66M$50.92M$38.09M$33.43M$25.11M$41.46M$26.61M
    Operating income-$23.50M-$23.78M-$19.67M-$27.93M-$15.77M-$1.29M$22.62M$17.68M$4.11M-$8.45M$11.66M-$606.00K
    Net income-$20.00M-$20.67M-$18.25M-$26.51M-$14.23M-$154.00K$23.52M$18.88M$5.74M-$6.53M$13.79M$837.00K
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $4.24M by $8.43M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$151.57M$120.53M$201.79M$260.89M$339.41M$358.66M$341.28M$457.11M$397.64M$199.13M
    Current assets$143.92M$107.31M$182.94M$237.10M$310.30M$324.01M$303.33M$445.48M$388.60M$188.15M
    Cash and equivalents$12.67M$38.05M$17.17M$193.65M$205.53M$191.86M$188.43M$247.58M$177.55M$104.64M
    Total liabilities$52.56M$120.99M$249.24M$346.64M$339.87M$366.44M$290.17M$326.23M$327.75M$120.65M
    Short-term debt$4.24M$5.14M$4.59M$4.08M$3.62M$3.19M$2.81M$13.34MN/AN/A
    Shareholder equity$99.01M-$456.00K-$47.45M-$85.75M-$459.00K-$7.77M$51.11M$130.88M$69.90M$78.48M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$364.68M$381.23M$359.36M$151.57M$158.25M$175.06M$98.50M$120.53M$138.98M$159.22M$184.69M$201.79M
    Total liabilities$79.79M$79.16M$39.41M$52.56M$50.87M$55.15M$73.45M$120.99M$162.43M$190.45M$216.37M$249.24M
    Cash and equivalents$33.96M$17.22M$28.83M$12.67M$34.19M$49.04M$47.60M$38.05M$40.58M$43.25M$36.19M$17.17M
    Shareholder equity$284.89M$302.07M$319.94M$99.01M$107.39M$119.91M$25.05M-$456.00K-$23.45M-$31.23M-$31.68M-$47.45M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$75.59M-$86.23M-$56.03M-$110.79M-$119.03M$5.26M-$140.48M-$75.52M$170.37M-$2.03M
    Capital expenditures$220.00K$310.00K$840.00K$1.74M$1.61M$2.31M$3.50M$3.79M$1.56M$2.18M
    Free cash flow-$75.81M-$86.54M-$56.88M-$112.53M-$120.64M$2.95M-$143.98M-$79.31M$168.81M-$4.21M
    Dividends paid$3.00MN/AN/AN/AN/AN/AN/AN/A$0$0
    Share repurchasesN/AN/AN/AN/AN/AN/AN/AN/AN/A$12.00K
    Investing cash flow-$59.74M$99.70M-$150.67M$98.26M$22.49M-$18.72M$79.70M$5.93M-$121.27M$45.86M
    Financing cash flow$110.45M$7.52M$30.23M$648.00K$110.21M$16.89M$1.63M$139.62M$23.80M$996.00K
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow$16.65M-$18.07M-$25.55M-$23.24M-$15.55M-$15.75M-$21.04M-$19.91M-$20.73M-$19.55M-$26.05M-$21.96M
    Capital expenditures$589.00KN/A$0$201.00K$127.00K$27.00K$119.00K$80.00K$19.00K$96.00K$115.00K$266.00K
    Free cash flow$16.06MN/A-$25.55M-$23.44M-$15.68M-$15.78M-$21.16M-$19.99M-$20.75M-$19.64M-$26.16M-$22.23M
    Last 12 quarters

    Frequently Asked Questions About CTMX

    What is CytomX Therapeutics' annual revenue?

    CytomX Therapeutics reported revenue of $76.20M for the fiscal year ended Dec 31, 2025.

    How fast is CytomX Therapeutics' revenue growing?

    Revenue was down 44.8% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 12.8%.

    Is CytomX Therapeutics profitable?

    No. CytomX Therapeutics reported net income of -$17.37M for the fiscal year ended Dec 31, 2025, with a net margin of -22.8%.

    How much free cash flow does CTMX generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$75.59M minus capital expenditures of $220.00K produced free cash flow of -$75.81M.

    How much debt does CytomX Therapeutics have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $4.24M and cash and equivalents of $12.67M.